This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

IONIS-BIIB5Rx

Biogen, Inc.

Drug Names(s): IONIS-BIIB5 Rx

Description: IONIS-BIIB5Rx is being developed with Biogen and is designed to address an undisclosed target for the treatment of patients with neurodegenerative diseases.

Deal Structure: Isis and Biogen Idec
In September 2013, Biogen Idec and Isis announced that the companies have entered into a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases.

As part of the six-year research collaboration, Biogen Idec will gain exclusive rights to the use of Isis' antisense technology to develop therapies for neurological diseases. Terms of this collaboration include: